Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.

Autor: Holman RR; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom. Electronic address: rury.holman@dtu.ox.ac.uk., Bethel MA; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom., Chan JC; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong., Chiasson JL; CRCHUM, Department of Medicine, University of Montreal, Montreal, Canada., Doran Z; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom., Ge J; Zhongshan Hospital, Fudan University, Shanghai, China., Gerstein H; Department of Medicine and Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Ontario, Canada., Huo Y; Department of Cardiology, Peking University First Hospital, Beijing, China., McMurray JJ; Institute of Cardiovascular & Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom., Ryden L; Cardiology Unit, Karolinska University Hospital Solna, Stockholm, Sweden., Liyanage W; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom., Schröder S; Bayer Healthcare, Bayer Pharma AG, Berlin, Germany., Tendera M; 3rd Division of Cardiology, Medical University of Silesia, Katowice, Poland., Theodorakis MJ; Diabetes Trials Unit, University of Oxford, Oxford, United Kingdom., Tuomilehto J; Centre for Vascular Prevention, Danube-University Krems, Krems, Austria; Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland; King Abdulaziz University, Jeddah, Saudi Arabia., Yang W; China-Japan Friendship Hospital, Beijing, China., Hu D; People's Hospital of Peking University, Beijing, China., Pan C; Department of Endocrinology, People's Liberation Army General Hospital, Beijing, China.
Jazyk: angličtina
Zdroj: American heart journal [Am Heart J] 2014 Jul; Vol. 168 (1), pp. 23-9.e2. Date of Electronic Publication: 2014 Apr 05.
DOI: 10.1016/j.ahj.2014.03.021
Abstrakt: Patients with cardiovascular disease and impaired glucose tolerance are at increased risk of cardiovascular events and type 2 diabetes mellitus (T2DM). Lifestyle modification or pharmacological intervention can delay progression to T2DM, but there is no clear evidence that they reduce cardiovascular risk in this population. Acarbose, an α-glucosidase inhibitor that lowers postprandial blood glucose, has been shown to reduce T2DM risk by 25%, and possibly cardiovascular risk in impaired glucose tolerance subjects without cardiovascular disease.
(Copyright © 2014 Mosby, Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: